Correlates of protection: novel generations of influenza vaccines - PubMed

Review

Correlates of protection: novel generations of influenza vaccines

Guus F Rimmelzwaan et al. Vaccine. 2008.

Abstract

The emergence of avian influenza A/H5N1 viruses that can cross the species barrier and that cause often-fatal infections of humans is of great concern and a pandemic outbreak with these viruses is feared. The availability of effective vaccines that can protect against morbidity and mortality caused by these viruses is highly desirable and great efforts are being made to prepare these vaccines. The circulation of variants of antigenically distinct influenza H5N1 viruses belonging to different clades complicates the development of new vaccines. Preferably, vaccines induce broad protective immunity against intra-subtypic variants and ideally, also hetero-subtypic immunity. A good understanding of the correlates of immune protection may aid in the development of such vaccines. Here we reviewed potential correlates of protection against influenza and discussed some of the vaccination strategies that could result in optimal protection against epidemic and pandemic influenza.

Similar articles

• Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.

  Sun X, Belser JA, Pulit-Penaloza JA, Creager HM, Guo Z, Jefferson SN, Liu F, York IA, Stevens J, Maines TR, Jernigan DB, Katz JM, Levine MZ, Tumpey TM. Sun X, et al. Virology. 2017 Aug;508:164-169. doi: 10.1016/j.virol.2017.05.010. Epub 2017 May 26. Virology. 2017. PMID: 28554058 Free PMC article.

• An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.

  Leung HC, Chan CC, Poon VK, Zhao HJ, Cheung CY, Ng F, Huang JD, Zheng BJ. Leung HC, et al. Emerg Microbes Infect. 2015 Apr;4(4):e22. doi: 10.1038/emi.2015.22. Epub 2015 Apr 8. Emerg Microbes Infect. 2015. PMID: 26038770 Free PMC article.

• Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control.

  Kreijtz JH, Osterhaus AD, Rimmelzwaan GF. Kreijtz JH, et al. Hum Vaccin. 2009 Mar;5(3):126-35. doi: 10.4161/hv.5.3.6986. Epub 2009 Mar 15. Hum Vaccin. 2009. PMID: 18948744 Review.

• The threat of avian influenza A (H5N1). Part IV: Development of vaccines.

  Cinatl J Jr, Michaelis M, Doerr HW. Cinatl J Jr, et al. Med Microbiol Immunol. 2007 Dec;196(4):213-25. doi: 10.1007/s00430-007-0052-3. Epub 2007 Jun 1. Med Microbiol Immunol. 2007. PMID: 17541633 Review.

• Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.

  Boonnak K, Matsuoka Y, Wang W, Suguitan AL Jr, Chen Z, Paskel M, Baz M, Moore I, Jin H, Subbarao K. Boonnak K, et al. J Virol. 2017 Jul 12;91(15):e00547-17. doi: 10.1128/JVI.00547-17. Print 2017 Aug 1. J Virol. 2017. PMID: 28490598 Free PMC article.

Cited by

• Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines.

  Manicassamy B, Medina RA, Hai R, Tsibane T, Stertz S, Nistal-Villán E, Palese P, Basler CF, García-Sastre A. Manicassamy B, et al. PLoS Pathog. 2010 Jan 29;6(1):e1000745. doi: 10.1371/journal.ppat.1000745. PLoS Pathog. 2010. PMID: 20126449 Free PMC article.

• Antigen spacing on protein nanoparticles influences antibody responses to vaccination.

  Ellis D, Dosey A, Boyoglu-Barnum S, Park YJ, Gillespie R, Syeda H, Tsybovsky Y, Murphy M, Pettie D, Matheson N, Chan S, Ueda G, Fallas JA, Carter L, Graham BS, Veesler D, Kanekiyo M, King NP. Ellis D, et al. bioRxiv [Preprint]. 2023 May 24:2023.05.23.541980. doi: 10.1101/2023.05.23.541980. bioRxiv. 2023. PMID: 37292995 Free PMC article. Updated. Preprint.

• Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques.

  Jegaskanda S, Amarasena TH, Laurie KL, Tan HX, Butler J, Parsons MS, Alcantara S, Petravic J, Davenport MP, Hurt AC, Reading PC, Kent SJ. Jegaskanda S, et al. J Virol. 2013 Dec;87(24):13706-18. doi: 10.1128/JVI.01666-13. Epub 2013 Oct 9. J Virol. 2013. PMID: 24109221 Free PMC article.

• Methylglycol chitosan and a synthetic TLR4 agonist enhance immune responses to influenza vaccine administered sublingually.

  Spinner JL, Oberoi HS, Yorgensen YM, Poirier DS, Burkhart DJ, Plante M, Evans JT. Spinner JL, et al. Vaccine. 2015 Oct 26;33(43):5845-5853. doi: 10.1016/j.vaccine.2015.08.086. Epub 2015 Sep 21. Vaccine. 2015. PMID: 26392012 Free PMC article.

• Differential recognition of influenza A virus H1N1 neuraminidase by DNA vaccine-induced antibodies in pigs and ferrets.

  Tingstedt JL, Stephen C, Risinger C, Blixt O, Gunalan V, Johansen IS, Fomsgaard A, Polacek C, Lassaunière R. Tingstedt JL, et al. Front Immunol. 2023 May 29;14:1200718. doi: 10.3389/fimmu.2023.1200718. eCollection 2023. Front Immunol. 2023. PMID: 37313410 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information